Annual Report Reveals 23% Drop in Operating Profit and Significant $919M Impairment Charge on Skin Health Business

summarizeSummary

Colgate-Palmolive reported a 23% decrease in operating profit and a 26% drop in net income for 2025, largely due to a $919 million impairment charge on its skin health business, despite modest organic sales growth and continued capital returns to shareholders.

check_boxKey Events

• Significant Impairment Charge

  The company recorded a $919 million pre-tax ($794 million after-tax) goodwill and intangible assets impairment charge in Q4 2025, primarily related to its Filorga skin health business due to lower-than-expected category growth and performance, especially in China.

• Substantial Profit Decline

  GAAP operating profit decreased by 23% to $3,306 million in 2025 from $4,268 million in 2024, and diluted EPS fell by 25.1% to $2.63 from $3.51, largely impacted by the impairment charge.

• Modest Sales Growth

  Net sales increased by 1.4% to $20,382 million in 2025, with organic sales also growing by 1.4%, driven by net selling price increases.

• New Share Repurchase Program and Dividend Increase

  The Board authorized a new $5 billion share repurchase program in March 2025 and increased the quarterly common stock dividend to $0.52 per share, demonstrating a commitment to returning capital to shareholders.

auto_awesomeAnalysis

Colgate-Palmolive's annual report for 2025 highlights a substantial decline in GAAP operating profit and net income, primarily driven by a significant goodwill and intangible asset impairment charge related to its skin health business. This impairment, totaling $919 million pre-tax, indicates underperformance in a key segment, particularly in China. While the company reported modest organic sales growth and continued shareholder returns through dividends and a new share repurchase program, the overall financial results reflect a challenging operating environment and a material hit to profitability. Investors should monitor the performance of the skin health segment and the effectiveness of the new Strategic Growth and Productivity Program in mitigating future cost pressures and driving growth amidst a cautious macroeconomic outlook.